GlassScriptPhysician profile
Stephanie Ferron
NPI 1134701261
$4,389.60
in general payments reported to CMS, 2019-2025
44 companies · $2,770 in 2025
The $2,770 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $99.54 · 2023: $323 · 2024: $1,197 · 2025: $2,770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,223 · Education: $67.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,223.06 |
| Education | $67.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $593.55 | 2023-2025 | |
| Abbvie INC. | $500.50 | 2024-2025 | |
| Tg Therapeutics, INC. | $284.18 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $224.35 | 2024-2025 | Ultomiris |
| Biogen, INC. | $204.73 | 2024-2025 | Vumerity, Tysabri, Skyclarys |
| Uswm, LLC | $164.51 | 2023-2024 | Lucemyra, Zimhi |
| Merz Pharmaceuticals, LLC | $150.60 | 2024-2025 | Xeomin, Inbrija, Ampyra |
| Ucb, INC. | $145.09 | 2024-2025 | Briviact, Zilbrysq, Rystiggo |
| Novartis Pharmaceuticals Corporation | $140.96 | 2024-2025 | |
| Amgen INC. | $132.62 | 2024-2025 | Uplizna |
| Sk Life Science, INC. | $126.78 | 2024-2025 | Xcopri |
| Neurocrine Biosciences, INC. | $121.61 | 2024-2025 | Ingrezza |
| Emd Serono, INC. | $119.04 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $117.96 | 2024-2025 | |
| Lundbeck LLC | $107.13 | 2023-2024 | Vyepti |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $87.80 | 2024-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.05 | 2024 | Relistor |
| Vanda Pharmaceuticals INC. | $70.58 | 2025 | Ponvory |
| Neurelis, INC. | $68.41 | 2024-2025 | Valtoco |
| Scilex Pharmaceuticals INC. | $67.88 | 2022-2024 | Ztlido |
| Mallinckrodt Hospital Products INC. | $66.30 | 2025 | Acthar |
| Catalyst Pharmaceuticals, INC. | $59.83 | 2025 | |
| Collegium Pharmaceutical, INC. | $58.46 | 2022-2024 | Xtampza |
| Argenx US, INC. | $53.55 | 2025 | Vyvgart Hytrulo |
| Tanabe Pharma America, INC. | $51.60 | 2024-2025 | Radicava |
| Harmony Biosciences LLC | $49.53 | 2024-2025 | |
| Genzyme Corporation | $48.91 | 2025 | |
| Averitas Pharma INC. | $47.43 | 2024-2025 | Qutenza |
| Genentech USA, INC. | $47.13 | 2025 | Ocrevus Zunovo |
| Lilly USA, LLC | $42.89 | 2024-2025 | Kisunla, Reyvow, Emgality |
| Otsuka America Pharmaceutical, INC. | $42.14 | 2024 | Rexulti |
| Ani Pharmaceuticals, INC. | $39.04 | 2025 | Purified Cortrophin Gel |
| Axsome Therapeutics, INC. | $34.53 | 2025 | Symbravo |
| Merck Sharp & Dohme LLC | $29.78 | 2022 | |
| 180 Medical, INC. | $24.79 | 2024 | Gentlecath Glide |
| Ge Healthcare | $24.74 | 2025 | |
| Celgene Corporation | $24.28 | 2024 | Zeposia |
| Eisai INC. | $24.26 | 2024 | |
| Springworks Therapeutics, INC. | $22.03 | 2025 | Gomekli |
| Csl Behring | $19.59 | 2025 | Hizentra |
| Life Molecular Imaging LTD | $19.16 | 2025 | Neuraceq |
| Kowa Pharmaceuticals America, INC. | $17.63 | 2022 | |
| Brainsway USA INC | $17.44 | 2023 | |
| Arbor Pharmaceuticals, INC. | $16.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Ferron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.